{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:20:58Z","timestamp":1780539658626,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170188"],"award-info":[{"award-number":["81170188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Chongqing","award":["CSCT 2009BB5069"],"award-info":[{"award-number":["CSCT 2009BB5069"]}]},{"name":"Chongqing Municipal Health and Family Planning Commission","award":["2016HBRC001"],"award-info":[{"award-number":["2016HBRC001"]}]},{"name":"Chongqing Municipal Health and Family Planning Commission","award":["2016XMSB0003767"],"award-info":[{"award-number":["2016XMSB0003767"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jjcc.2017.10.018","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T09:47:33Z","timestamp":1511776053000},"page":"494-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"given":"Xiaofang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schulz-Sch\u00fcpke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedid","family":"Elbez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McAndrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2017.10.018_bib0215","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2011.08.051","article-title":"Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease","volume":"58","author":"Basra","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijcard.2009.03.119","article-title":"Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY","volume":"144","author":"Spinler","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/14628840510011298","article-title":"Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function","volume":"7","author":"Roguin","year":"2005","journal-title":"Int J Cardiovasc Intervent"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/5584_2016_109","article-title":"Anticoagulation therapy in patients with chronic kidney disease","volume":"906","author":"Saheb Sharif-Askari","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0240","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcin.2011.05.022","article-title":"Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention","volume":"4","author":"Hanna","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0245","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40620-015-0184-2","article-title":"How to balance risks and benefits in the management of CKD patients with coronary artery disease","volume":"28","author":"Marenzi","year":"2015","journal-title":"J Nephrol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0255","first-page":"115","article-title":"Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty","volume":"8","author":"Shah","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0260","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0265","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0275","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jcin.2009.05.018","volume":"2","author":"Mehran","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0285","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0290","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0295","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jcin.2011.06.012","volume":"4","author":"Saltzman","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0300","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.amjcard.2004.11.003","article-title":"Bivalirudin versus heparin and glycoprotein IIb\/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)","volume":"95","author":"Chew","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0310","first-page":"663","article-title":"The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk","volume":"23","author":"Fitchett","year":"2007","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0315","first-page":"5","article-title":"Antiplatelet agents and anticoagulants in patients with chronic kidney disease \u2013 from pathophysiology to clinical practice","volume":"5","author":"Lutz","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0320","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107424840501000401","article-title":"Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis","volume":"10","author":"Ebrahimi","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0325","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/CIRCINTERVENTIONS.113.000554","article-title":"Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb\/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium","volume":"6","author":"Perdoncin","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0330","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIR.0000000000000183","article-title":"Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association","volume":"131","author":"Washam","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0335","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11739-008-0164-9","article-title":"Low-molecular-weight heparin in patients with chronic renal insufficiency","volume":"3","author":"Lim","year":"2008","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0340","article-title":"The use of bivalirudin in patients with renal impairment","volume":"12","author":"Robson","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/clc.20974","article-title":"Efficacy and safety of unfractionated heparin plus glycoprotein IIb\/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines","volume":"35","author":"Winchester","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0350","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jcin.2010.03.015","article-title":"Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry","volume":"3","author":"Lopes","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0355","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/14796678.3.4.345","article-title":"Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin","volume":"3","author":"Nikolsky","year":"2007","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0360","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1074248410385682","article-title":"Clinical applications of bivalirudin in the cardiac catheterization laboratory","volume":"16","author":"Thompson","year":"2011","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0365","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/14656566.3.6.777","article-title":"Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions","volume":"3","author":"White","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0370","doi-asserted-by":"crossref","first-page":"V275","DOI":"10.1016\/S0049-3848(02)00093-2","article-title":"Direct thrombin inhibitors","volume":"106","author":"Weitz","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0375","first-page":"73","article-title":"Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal","volume":"69","author":"Cantor","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0380","first-page":"237","article-title":"Anticoagulation in transradial percutaneous coronary intervention","volume":"83","author":"Appleton","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0385","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4244\/EIJV7I8A144","article-title":"Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial","volume":"7","author":"Genereux","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0390","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MCA.0000000000000096","article-title":"Bleeding complications in patients undergoing percutaneous coronary interventions: current status and perspective","volume":"25","author":"Ndrepepa","year":"2014","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0395","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4244\/EIJV5I1A18","article-title":"Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial","volume":"5","author":"Hamon","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2015.10.006","article-title":"An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention","volume":"171","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0405","doi-asserted-by":"crossref","first-page":"e001645","DOI":"10.1161\/CIRCINTERVENTIONS.114.001645","article-title":"Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis","volume":"8","author":"Kwok","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0410","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/heartjnl-2013-304564","article-title":"Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention","volume":"100","author":"Matic","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0415","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2017.10.018_bib0420","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450871730309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450871730309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:58:26Z","timestamp":1760273906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S091450871730309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S091450871730309X"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2017.10.018","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2017.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}